Alvaro Alencar, MD

Alvaro Alencar, MD, discusses research needed to clarify the optimal dosing, role, and sequencing of NX-5948 in CLL and other B-cell malignancies.

Alvaro Alencar, MD, discusses current unmet needs following the development of covalent BTK inhibitor resistance in CLL.

Alvaro Alencar, MD, explains the rationale of a phase 1 trial investigating NX-5948, a BTK degrader, in chronic lymphocytic leukemia.

Alvaro Alencar, MD, discusses the preliminary efficacy and safety of NX-5948, a BTK degrader, in patients with chronic lymphocytic leukemia.